More Progress Made Towards the Development of an Artificial Pancreas

July 7th, 2011

Researchers are continuing to make progress in the development of an artificial pancreas for insulin dependent type 1 diabetics. An artificial pancreas is an automated, closed-loop system consisting of a continuous glucose monitor, a glucose meter to calibrate the monitor, and an insulin pump.

With the help of a sophisticated computer system, an artificial pancreas produces insulin and controls blood sugar in a diabetic much as a normal pancreas does in a person without diabetes. The sophisticated system senses when the body needs insulin, calculates the dose needed, and delivers automatically, eliminating the need for insulin injections.

To read more about several recent advances towards the development of an artificial pancreas on WebMD, >CLICK HERE<.

Successful Pilot Study for Implanted Continuous Glucose Monitor

September 13th, 2011

Sensors for Medicine and Science Inc (SMSI) is developing a new approach to glucose monitoring that promises to be a long-awaited improvement over present methods, which typically require several finger prick blood tests a day. This inconvenient and uncomfortable method of collecting blood samples results in many diabetics not testing their blood sugar as often as they should.

The new glucose monitoring method involves a small sensor that is implanted under the skin. The sensor automatically monitors glucose levels every few minutes, and transmits the information wirelessly to a small wrist-watch-like external reader. The sensor will also warn the wearer of an impending episode of low or high blood sugar.

The sensor would be of obvious benefit to insulin dependent diabetics whose diabetes is not well controlled or whose blood sugar levels swing unpredictably. It would also be ideal for children with diabetes.

Sensors for Medicine and Science will be presenting the results of a successful pilot study of the glucose monitor at the next meeting of the European Association for the Study of Diabetes. "Based on the promising results obtained," says CEO Tim Goodnow, PhD, "We plan to initiate more clinical trials in the very near future."

The company also hopes to collaborate on artificial pancreas research, with many questions to be answered.